Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel Group, 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
NCT00542685 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel Group, 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- Lead sponsor
- Pfizer
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2007
- Completion date
- December 31, 2008
- Enrollment
- 551 (actual)
- Sites
- 43
Conditions
As the registry lists them; a condition with its own page is linked.